![Recurrence-free survival versus overall survival as a primary endpoint for studies of resected colorectal liver metastasis: a retrospective study and meta-analysis - The Lancet Oncology Recurrence-free survival versus overall survival as a primary endpoint for studies of resected colorectal liver metastasis: a retrospective study and meta-analysis - The Lancet Oncology](https://www.thelancet.com/cms/attachment/618e2e54-f852-4d2c-b869-631693d2c1b8/gr1_lrg.jpg)
Recurrence-free survival versus overall survival as a primary endpoint for studies of resected colorectal liver metastasis: a retrospective study and meta-analysis - The Lancet Oncology
![Comparison of disease-free survival (A) and overall survival (B) among... | Download Scientific Diagram Comparison of disease-free survival (A) and overall survival (B) among... | Download Scientific Diagram](https://www.researchgate.net/publication/331693832/figure/fig2/AS:865091390017536@1583265268233/Comparison-of-disease-free-survival-A-and-overall-survival-B-among-HCC-ICC-and.png)
Comparison of disease-free survival (A) and overall survival (B) among... | Download Scientific Diagram
![Definition of progression free survival and overall survival for the... | Download Scientific Diagram Definition of progression free survival and overall survival for the... | Download Scientific Diagram](https://www.researchgate.net/publication/265644752/figure/fig1/AS:269802786783234@1441337405030/Definition-of-progression-free-survival-and-overall-survival-for-the-Gold-standard-and.png)
Definition of progression free survival and overall survival for the... | Download Scientific Diagram
![Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis - The Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis - The](https://www.thelancet.com/cms/attachment/2cbba9be-95f0-4764-ad55-25b5e2074383/gr1.gif)
Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis - The
![Comparison of disease-free survival (DFS) and overall survival (OS)... | Download Scientific Diagram Comparison of disease-free survival (DFS) and overall survival (OS)... | Download Scientific Diagram](https://www.researchgate.net/publication/273956724/figure/fig2/AS:282745193418754@1444423115791/Comparison-of-disease-free-survival-DFS-and-overall-survival-OS-according-to-the.png)
Comparison of disease-free survival (DFS) and overall survival (OS)... | Download Scientific Diagram
![Multimodality management of gallbladder cancer can lead to a better outcome: Experience from a tertiary care oncology centre in North India Multimodality management of gallbladder cancer can lead to a better outcome: Experience from a tertiary care oncology centre in North India](https://f6publishing.blob.core.windows.net/86338a8e-a170-4c94-aa06-3b0be1980f14/WJG-27-7813-g002.png)
Multimodality management of gallbladder cancer can lead to a better outcome: Experience from a tertiary care oncology centre in North India
Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma | Haematologica
![VisualAbstract: Effect of Laparoscopic vs Open Distal Gastrectomy on 3-Year Disease-Free Survival in Patients With Locally Advanced Gastric Cancer | 2 Minute Medicine VisualAbstract: Effect of Laparoscopic vs Open Distal Gastrectomy on 3-Year Disease-Free Survival in Patients With Locally Advanced Gastric Cancer | 2 Minute Medicine](https://www.2minutemedicine.com/wp-content/uploads/2019/07/2MM_VA_6.1.2019_2.jpg)
VisualAbstract: Effect of Laparoscopic vs Open Distal Gastrectomy on 3-Year Disease-Free Survival in Patients With Locally Advanced Gastric Cancer | 2 Minute Medicine
![Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis - The Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis - The](https://www.thelancet.com/cms/attachment/6f00f669-f048-4578-a489-bf14cf2f4811/gr3.jpg)
Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis - The
High ECT2 expression is an independent prognostic factor for poor overall survival and recurrence-free survival in non-small cell lung adenocarcinoma | PLOS ONE
![Estimating progression-free survival in patients with glioblastoma using routinely collected data | SpringerLink Estimating progression-free survival in patients with glioblastoma using routinely collected data | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs11060-017-2619-1/MediaObjects/11060_2017_2619_Fig1_HTML.gif)
Estimating progression-free survival in patients with glioblastoma using routinely collected data | SpringerLink
![The Disease-Free Interval Between Resection of Primary Colorectal Malignancy and the Detection of Hepatic Metastases Predicts Disease Recurrence But Not Overall Survival | SpringerLink The Disease-Free Interval Between Resection of Primary Colorectal Malignancy and the Detection of Hepatic Metastases Predicts Disease Recurrence But Not Overall Survival | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1245%2Fs10434-019-07481-x/MediaObjects/10434_2019_7481_Fig1_HTML.png)
The Disease-Free Interval Between Resection of Primary Colorectal Malignancy and the Detection of Hepatic Metastases Predicts Disease Recurrence But Not Overall Survival | SpringerLink
![The Importance of Disease-Free Survival as a Clinical Trial Endpoint: A Qualitative Study Among Canadian Survivors of Lung Cancer | SpringerLink The Importance of Disease-Free Survival as a Clinical Trial Endpoint: A Qualitative Study Among Canadian Survivors of Lung Cancer | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40271-021-00552-w/MediaObjects/40271_2021_552_Fig1_HTML.png)
The Importance of Disease-Free Survival as a Clinical Trial Endpoint: A Qualitative Study Among Canadian Survivors of Lung Cancer | SpringerLink
![The Importance of Disease-Free Survival as a Clinical Trial Endpoint: A Qualitative Study Among Canadian Survivors of Lung Cancer | SpringerLink The Importance of Disease-Free Survival as a Clinical Trial Endpoint: A Qualitative Study Among Canadian Survivors of Lung Cancer | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40271-021-00552-w/MediaObjects/40271_2021_552_Fig2_HTML.png)
The Importance of Disease-Free Survival as a Clinical Trial Endpoint: A Qualitative Study Among Canadian Survivors of Lung Cancer | SpringerLink
![Overall survival vs disease-free survival and other surrogate endpoints - interpretation - Datamethods Discussion Forum Overall survival vs disease-free survival and other surrogate endpoints - interpretation - Datamethods Discussion Forum](https://discourse.datamethods.org/uploads/default/original/2X/0/00c7385e94688a19921c14a15730ba55e0e5dd17.png)
Overall survival vs disease-free survival and other surrogate endpoints - interpretation - Datamethods Discussion Forum
![Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials - London - 2017 - Cancer - Wiley Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials - London - 2017 - Cancer - Wiley](https://acsjournals.onlinelibrary.wiley.com/cms/asset/7ec0391a-b577-4b44-aac8-535a76de8de5/cncr30934-fig-0001-m.jpg)
Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials - London - 2017 - Cancer - Wiley
![Overall survival (a) and disease-free survival (b) among the entire... | Download Scientific Diagram Overall survival (a) and disease-free survival (b) among the entire... | Download Scientific Diagram](https://www.researchgate.net/publication/341610359/figure/fig2/AS:894767768539136@1590340668089/Overall-survival-a-and-disease-free-survival-b-among-the-entire-cohort-NO-number.png)
Overall survival (a) and disease-free survival (b) among the entire... | Download Scientific Diagram
![Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials - ScienceDirect Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0959804919307488-gr1.jpg)
Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials - ScienceDirect
![Disease-free survival landmark analysis: a potential critical endpoint in triple-negative breast cancer | Experimental Hematology & Oncology | Full Text Disease-free survival landmark analysis: a potential critical endpoint in triple-negative breast cancer | Experimental Hematology & Oncology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs40164-022-00308-8/MediaObjects/40164_2022_308_Fig1_HTML.png)
Disease-free survival landmark analysis: a potential critical endpoint in triple-negative breast cancer | Experimental Hematology & Oncology | Full Text
![Frontiers | Disease-Free Survival at 2 and 3 Years is a Significant Early Surrogate Marker Predicting the 5-Year Overall Survival in Patients Treated with Radical Cystectomy for Urothelial Carcinoma of the Bladder: Frontiers | Disease-Free Survival at 2 and 3 Years is a Significant Early Surrogate Marker Predicting the 5-Year Overall Survival in Patients Treated with Radical Cystectomy for Urothelial Carcinoma of the Bladder:](https://www.frontiersin.org/files/Articles/167493/fonc-05-00246-HTML-r1/image_m/fonc-05-00246-g001.jpg)